Information Provided By:
Fly News Breaks for July 28, 2016
BMRN
Jul 28, 2016 | 09:14 EDT
BMO Capital analyst M. Ian Somaiya says that the clinical update on BioMarin's hemophilia A treatment, BMN-270, "started to address safety concerns related to immunogenicity and liver enzyme elevations and, importantly, suggested that BMN-270 could be curative for some patients." The analyst raised his estimated probability for the drug's success to 50% from 30% and raised his price target on the shares to $118 from $108. He keeps an Outperform rating on the shares.
News For BMRN From the Last 2 Days
There are no results for your query BMRN